GlobeNewswire: Fate Therapeutics, Inc. Contains the last 10 of 298 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T05:59:41ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/05/2840880/0/en/Fate-Therapeutics-Reports-New-Employee-Inducement-Award-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=18463Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)2024-03-05T21:01:00Z<![CDATA[SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company granted a non-qualified stock option to one newly-hired employee to purchase a total of 40,000 shares of the Company’s common stock at an exercise price per share of $7.74, which was the closing price per share of the Company’s common stock as reported by NASDAQ on the grant effective date of March 1, 2024. The option was approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The option vests over four years, with 25% vesting on the one-year anniversary of the grant date and the remaining 75% percent vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date.]]>https://www.globenewswire.com/news-release/2024/03/01/2838787/0/en/Fate-Therapeutics-to-Present-at-Upcoming-March-Investor-Conferences.html?f=22&fvtc=4&fvtv=18463Fate Therapeutics to Present at Upcoming March Investor Conferences2024-03-01T13:00:00Z<![CDATA[SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences:]]>https://www.globenewswire.com/news-release/2024/02/26/2835475/0/en/Fate-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Business-Updates.html?f=22&fvtc=4&fvtv=18463Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates2024-02-26T21:01:00Z<![CDATA[CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus; Study Start-up Ongoing at Multiple Clinical Sites]]>https://www.globenewswire.com/news-release/2024/02/15/2829883/0/en/Fate-Therapeutics-to-Webcast-Conference-Call-Reporting-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=18463Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results2024-02-15T13:00:00Z<![CDATA[SAN DIEGO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Monday, February 26, 2024 at 5:00 PM ET to report its fourth quarter and full year 2023 financial results and provide a corporate update.]]>https://www.globenewswire.com/news-release/2024/02/02/2823042/0/en/Fate-Therapeutics-Reports-New-Employee-Inducement-Awards-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=18463Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)2024-02-02T21:01:00Z<![CDATA[SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that on February 1, 2024 the Company granted restricted stock units (RSUs) representing 32,600 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date.]]>https://www.globenewswire.com/news-release/2024/01/08/2805394/0/en/Fate-Therapeutics-Announces-Initiation-of-Phase-1-Clinical-Trial-for-FT825-ONO-8250-in-Patients-with-HER2-expressing-Advanced-Solid-Tumors.html?f=22&fvtc=4&fvtv=18463Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors2024-01-08T13:00:00Z<![CDATA[iPSC-derived CAR T-cell Product Candidate Incorporates Seven Synthetic Controls of Cell Function including a Novel HER2-targeted Antigen Binding Domain]]>https://www.globenewswire.com/news-release/2023/12/13/2795906/0/en/Fate-Therapeutics-Reports-New-Employee-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=18463Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2023-12-13T22:00:00Z<![CDATA[SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company granted a non-qualified stock option to one newly-hired employee to purchase a total of 350,000 shares of the Company’s common stock at an exercise price per share of $2.28, which was the closing price per share of the Company’s common stock as reported by NASDAQ on the grant effective date of December 11, 2023. The option was approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The option vests over four years, with 25% vesting on the one-year anniversary of the grant date and the remaining 75% percent vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date.]]>https://www.globenewswire.com/news-release/2023/11/08/2776652/0/en/Fate-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Business-Updates.html?f=22&fvtc=4&fvtv=18463Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates2023-11-08T21:01:00Z<![CDATA[Phase 1 Study Open for Enrollment of FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning Chemotherapy]]>https://www.globenewswire.com/news-release/2023/10/25/2766437/0/en/Fate-Therapeutics-to-Webcast-Conference-Call-Reporting-Third-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=18463Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results2023-10-25T12:00:00Z<![CDATA[SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2023 at 5:00 PM ET to report its third quarter 2023 financial results and provide a corporate update.]]>https://www.globenewswire.com/news-release/2023/08/31/2735188/0/en/Fate-Therapeutics-to-Present-at-Upcoming-September-Investor-Conferences.html?f=22&fvtc=4&fvtv=18463Fate Therapeutics to Present at Upcoming September Investor Conferences2023-08-31T12:00:00Z<![CDATA[SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences:]]>